tapebrief
JNJ · Q1 2026

JNJ · Q2 2026 Earnings

Neutral

Johnson & Johnson

Reported July 15, 2026

30-second summary

J&J posted Q2 revenue of $25.31B (+6.6% YoY, +1.0% ahead of $25.06B consensus) and adjusted EPS of $2.90 (+1.4% ahead of $2.86 consensus), with Oncology accelerating to +17.3% reported and MedTech decelerating further to +4.5% reported. The notable absence is the FY2026 guide refresh: after two consecutive quarters of raises in Q4 FY2025 and Q1 FY2026, the extracted materials show no updated FY2026 sales or EPS range this quarter — a break in the pre-signal cadence Wolk established through 2025.

Headline numbers

EPS

Q2 FY2026

$2.90

+1.4% vs est.

Revenue

Q2 FY2026

$25.31B

+6.6% YoY

+1.0% vs est.

Gross margin

Q2 FY2026

68.2%

Operating margin

Q2 FY2026

26.7%

Key financials

Q2 FY2026
MetricQ2 FY2026Q2 FY2025YoYQ1 FY2026QoQ
Revenue$25.31B$23.74B+6.6%$24.06B+5.2%
EPS$2.90$2.77+4.7%$2.70+7.4%
Gross margin68.2%67.9%+30bps66.3%+190bps
Operating margin26.7%27.3%-60bps——

Guidance

No forward guidance provided this quarter; unable to assess changes to FY2026 or Q3 FY2026 outlooks.

No forward guidance provided this quarter; unable to assess changes to FY2026 or Q3 FY2026 outlooks.

Segment KPIs

Q2 FY2026
SegmentQ2 FY2026Q2 FY2025YoY
Innovative Medicine$16.384B$15.202B+7.8%
MedTech$8.926B$8.541B+4.5%
Oncology (Innovative Medicine)$7.406B—+17.3%
Cardiovascular (MedTech)$2.404B—+4.0%
Innovative Medicine Operational Growth6.8%——
MedTech Operational Growth3.6%——
Oncology Segment Growth16.1%——

Other KPIs

Q2 FY2026
SegmentQ2 FY2026Q2 FY2025YoY
U.S.$14.533B$13.544B+7.3%
Europe$5.726B$5.387B+6.3%
Western Hemisphere excluding U.S.$1.309B$1.206B+8.5%
Asia-Pacific, Africa$3.742B$3.606B+3.8%
Adjusted Operating Margin34.2%——
Adjusted Net Earnings Margin28.0%——
Darzalex Revenue$4,207M$3.539B—
International Revenue Growth (Operational)3.4%——
Currency Headwind Impact1.0% of total growth——

Management tone

Tone analysis unavailable — no transcript surfaced for Q2 FY2026. The following is inferred from the press-release datapoints only and is deliberately brief.

The narrative arc through five quarters — growth through LOE (Q2 FY2025) → "powerful new era of growth" (Q3 FY2025) → 2026 pre-signal converted to formal guide (Q4 FY2025) → guide raised on both metrics (Q1 FY2026) → quiet quarter with no explicit refresh (Q2 FY2026) — represents a break in cadence rather than a break in fundamentals. Revenue and EPS both beat consensus, Oncology remains structurally strong, and the H1 EPS run-rate ($5.60) is tracking to the FY $11.30–$11.50 range. Without transcript commentary, however, it is not possible to characterize whether MedTech deceleration to +3.6% operational was pushed back on by analysts, whether Icotide script trajectory was disclosed, or whether the December 8 Enterprise Business Review was previewed. All of these were carried forward from Q1's watch list and remain unresolved from the extracted materials.

Answers to last quarter's watch list

Q2 FY2026 MedTech operational growth — MedTech operational growth ran +3.6% in Q2, below the +5.5% threshold set as the validation line and below Q1's +4.6%. This is now the second consecutive quarter of MedTech operational growth decelerating, and it undermines Schmid's "2026 better than 2025" commitment unless H2 shows a sharp acceleration.
Resolved negatively
Icotide Q2 commercial proof points — The company did not disclose Icotide-specific revenue or script metrics in the extracted press-release fields. Whether transcript commentary provides forward proof points cannot be confirmed.
Not resolved
Adjusted tax rate trajectory — The Q2 adjusted tax rate is not surfaced in the extracted figures. The FY2026 adjusted operating margin improvement of "at least +50bps" is on track given Q2's 34.2% adj. pre-tax margin, but tax-rate progression toward the maintained full-year range cannot be assessed from the press-release extraction.
Continue monitoring
December 8 Enterprise Business Review — This event is future-dated and was not addressed in the extracted Q2 materials.
Continue monitoring
FY2026 guide refresh cadence — No refreshed FY2026 sales or EPS range surfaced in the extraction. If confirmed, this represents a break in the raise cadence set in Q4 FY2025 and Q1 FY2026 — with H1 revenue growth of +8.2% reported (well above the 6.4% FY midpoint), a tightening upward was the plausible outcome. Status: Resolved negatively (cadence broken; underlying data would have supported a raise).

What to watch into next quarter

Q3 FY2026 MedTech operational growth — Two consecutive quarters of deceleration (+4.6% → +3.6% operational) put the FY2026 MedTech thesis under pressure. Anything below +5.0% operational in Q3 forces a downward mix conversation for the segment; +6.0%+ would rehabilitate the H2 acceleration story.

Q3 FY2026 FY guide refresh — With H1 revenue tracking above the FY midpoint, watch whether Q3 brings the tightening upward that Q2 did not. A second consecutive quarter without a refresh would suggest management is holding fire for the December 8 EBR rather than through the quarterly cadence.

Icotide first quantified revenue disclosure — Q1 offered script counts (~1,500 patients written, 1,000+ unique customers); Q2 apparently did not. By Q3 the "one of J&J's largest products ever" framing needs a dollar figure attached to it.

Oncology deceleration trajectory — Q2 operational +16.1% vs Q1's +17.8% and Q4 FY2025's +21.9%. Some deceleration is expected as the base scales, but watch whether Q3 stabilizes above +15% or continues to slide toward the mid-teens.

December 8 Enterprise Business Review — The event that Q1 explicitly reserved for the end-of-decade double-digit framework is now less than two quarters out. Watch for pre-event teasers on peak-sales targets, ortho separation stranded-cost quantification, and post-spin margin uplift.

Sources

  1. Johnson & Johnson Q2 FY2026 Earnings Press Release (Exhibit 99.2), filed July 15, 2026 — https://www.sec.gov/Archives/edgar/data/200406/000020040626000146/a2026q2exhibit992.htm
  2. Tapebrief Q1 FY2026, Q4 FY2025, and Q3 FY2025 briefs for cross-quarter guidance and cadence context.
  3. Transcript for Q2 FY2026 not available at time of publication; tone and Q&A analysis pending.

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.